Quarterly Report

0001553350-20-001033.txt : 20201117 0001553350-20-001033.hdr.sgml : 20201117 20201117150207 ACCESSION NUMBER: 0001553350-20-001033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201117 DATE AS OF CHANGE: 20201117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MediXall Group, Inc. CENTRAL INDEX KEY: 0001601280 STANDARD INDUSTRIAL CLASSIFICATION: RAILROADS, LINE-HAUL OPERATING [4011] IRS NUMBER: 330864127 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-194337 FILM NUMBER: 201320830 BUSINESS ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 BUSINESS PHONE: 954-440-4678 MAIL ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 FORMER COMPANY: FORMER CONFORMED NAME: CONTINENTAL RAIL CORP DATE OF NAME CHANGE: 20140227 10-Q 1 mdxl_10q.htm QUARTERLY REPORT Quarterly Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________________to__________________________

Commission File Number: 333-194337

MediXall Group, Inc.

(Exact name of registrant as specified in its charter)


Nevada	33-0864127
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

2929 East Commercial Blvd., PH-D, Ft. Lauderdale, Florida	33308
(Address of principal executive offices)	(Zip Code)

954-440-4678

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer þ	Smaller reporting company þ
	Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes þ No ¨

As of November 17, 2020, the issuer had 96,510,930 shares of its common stock issued and outstanding.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

INDEX


		Page No.
PART I	FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS:	1
	Condensed Consolidated Balance Sheets at September 30, 2020 (unaudited) and December 31, 2019	1
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)	2
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2020 and 2019 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	14
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	18
ITEM 4.	CONTROLS AND PROCEDURES	18

PART II	OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	20
ITEM 1A.	RISK FACTORS	20
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	21
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	21
ITEM 4.	MINE SAFETY DISCLOSURES	21
ITEM 5.	OTHER INFORMATION	21
ITEM 6.	EXHIBITS	21
SIGNATURES		22

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


	September 30,			December 31,
	2020			2019
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	519,451		$	446,219
Prepaid expenses - related party		297,630			—
Total current assets		817,081			446,219

Furniture and equipment, net		27,536			21,662

Right-of-use-operating lease asset		61,425			113,395

Website and development costs		427,464			356,704

Total assets	$	1,333,506		$	937,980

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	348,489		$	160,780
Accounts payable and accrued expenses - related party		19,931			261,801
Operating lease liability		65,457			71,362

Total current liabilities		433,877			493,943

Operating lease liability, net of current portion		—			46,277
Long term debt		165,719			—

Total liabilities		599,596			540,220

STOCKHOLDERS' EQUITY:
Convertible Preferred Series A stock, $0.001 par value, 1,000,000 authorized; 264,894 issued and outstanding		265			265
Convertible Preferred Series B stock, $0.001 par value, 4,000,000 authorized; 777,560 issued and outstanding in 2020		778			—
Common Stock, $0.001 par value 750,000,000 shares authorized; 95,807,930 and 80,952,555 shares issued and outstanding		95,808			80,953
Additional paid-in capital		18,250,569			13,966,326
Accumulated deficit		(17,613,510	)		(13,649,784	)

Total stockholders' equity		733,910			397,760

Total liabilities and stockholders' equity	$	1,333,506		$	937,980

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2020			2019			2020			2019

Revenue	$	—		$	807		$	—		$	2,253

Operating Expenses
Professional fees		241,454			131,988			1,145,895			448,812
Professional fees - related party		104,050			55,725			245,050			186,275
Management fee - related party		120,000			120,000			360,000			360,000
Personnel related expenses		428,633			311,556			1,998,460			868,602
Other selling, general and administrative		72,494			96,416			214,321			268,205
Total Operating Expenses		966,631			715,685			3,963,726			2,131,894
Loss before income taxes		(966,631	)		(714,878	)		(3,963,726	)		(2,129,641	)
Income taxes		—			—			—			—
Net loss	$	(966,631	)	$	(714,878	)	$	(3,963,726	)	$	(2,129,641	)

Net loss per common share - basic and diluted	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.03	)

Weighted average number of common shares outstanding during the periods - basic and diluted		93,506,088			74,640,786			88,660,995			72,874,854

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2020 AND 2019


	Series A Voting				Series B Voting
	Preferred Stock				Preferred Stock				Common Stock				Additional					Total
	$0.001 Par Value				$0.001 Par Value				$0.001 Par Value				Paid-in		Accumulated			Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance, December 31, 2018		264,894	$	265		—	$	—		69,642,554	$	69,642	$	10,701,887	$	(10,228,833	)	$	542,961
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering cost (unaudited)		—		—		—		—		2,351,000		2,351		605,523		—			607,874
Common stock issued for services (unaudited)		—		—		—		—		240,000		240		124,760		—			125,000
Net loss (unaudited)		—		—		—		—		—		—		—		(744,398	)		(744,398	)
Balance, March 31, 2019 (unaudited)		264,894		265		—		—		72,233,554		72,233		11,432,170		(10,973,231	)		531,437
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering cost (unaudited)		—		—		—		—		1,471,500		1,472		390,155		—			391,627
Net loss (unaudited)		—		—		—		—		—		—		—		(670,365	)		(670,365	)
Balance, June 30, 2019 (unaudited)		264,894		265		—		—		73,705,054		73,705		11,822,325		(11,643,596	)		252,699
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering cost (unaudited)		—		—		—		—		1,711,000		1,711		631,289		—			633,000
Common stock issued for services (unaudited)		—		—		—		—		52,668		53		26,281		—			26,334
Net loss (unaudited)		—		—		—		—		—		—		—		(714,878	)		(714,878	)
Balance, September 30, 2019 (unaudited)		264,894	$	265		—	$	—		75,468,722	$	75,469	$	12,479,895	$	(12,358,474	)	$	197,155

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)(CONTINUED)

THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2020 AND 2019


	Series A Voting				Series B Voting
	Preferred Stock				Preferred Stock				Common Stock				Additional						Total
	$0.001 Par Value				$0.001 Par Value				$0.001 Par Value				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance, December 31, 2019		264,894	$	265		—		—		80,952,555	$	80,953	$	13,966,326		$	(13,649,784	)	$	397,760
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering cost (unaudited)		—		—		—		—		1,907,000		1,907		499,843			—			501,750
Common stock issued for services (unaudited)		—		—		—		—		3,964,375		3,964		1,039,101			—			1,043,065
Net loss (unaudited)		—		—		—		—		—		—		—			(1,851,085	)		(1,851,085	)
Balance, March 31, 2020 (unaudited)		264,894		265		—		—		86,823,930		86,824		15,505,270			(15,500,869	)		91,490
Proceeds received pursuant to Private Placement Memorandum, net of $3,000 offering cost (unaudited)		—		—				—		2,350,000		2,350		594,650			—			597,000
Proceeds received from sale of Preferred Stock (unaudited)		—		—		500,000		500		—		—		499,500			—			500,000
Common stock issued for services (unaudited)		—		—		—		—		1,880,000		1,880		468,120			—			470,000
Net loss (unaudited)		—		—		—		—		—		—		—			(1,146,010	)		(1,146,010	)
Balance, June 30, 2020 (unaudited)		264,894		265		500,000		500		91,053,930		91,054		17,067,540			(16,646,879	)		512,480
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering cost (unaudited)		—		—		—		—		3,754,000		3,754		906,746			—			910,500
Proceeds received from sale of Preferred Stock (unaudited)		—		—		277,560		278		—		—		277,283			—			277,561
Common stock issued to related party (unaudited)		—		—		—		—		1,000,000		1,000		(1,000	)		—			—
Net loss (unaudited)		—		—		—		—		—		—		—			(966,631	)		(966,631	)
Balance, September 30, 2020 (unaudited)		264,894	$	265		777,560	$	778		95,807,930	$	95,808	$	18,250,569		$	(17,613,510	)	$	733,910

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)


	Nine Months Ended
	September 30,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,963,726	)	$	(2,129,641	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		3,000			3,000
Stock issued as compensation for services		1,513,065			121,334
Changes in operating assets and liabilities:
Prepaid expenses - related party		(297,630	)		160,590
Accounts payable and accrued expenses		187,709			51,166
Accounts payable and accrued expenses - related party		(241,870	)		20,319
Right-of-use operating lease asset		51,970			49,047
Operating lease liability		(52,182	)		(44,991	)
Net cash used in operating activities		(2,799,664	)		(1,769,176	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment		(8,874	)		(8,880	)
Website development costs		(70,760	)		(5,247	)
Net cash used in investing activities		(79,634	)		(14,127	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of common stock, net of offering costs		2,009,250			1,632,501
Proceeds from the sale of preferred stock		777,561			—
Proceeds from long term debt		165,719			—
Net cash provided by financing activities		2,952,530			1,632,501

Net increase (decrease) in cash		73,232			(150,802	)
Cash at beginning of period		446,219			201,509

Cash at end of period	$	519,451		$	50,707

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period:
Interest	$	—		$	—
Income taxes	$	—		$	—

Non-cash transactions:
Reclassification of stock compensation from other liabilities to common stock	$	—		$	30,000
Right-of-use asset obtained in exchange for operating lease liabilities	$	—		$	179,341
Common stock issued to related party	$	1,000		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1 - Organization and Nature of Operation

MediXall Group, Inc. (the "Company “or “MediXall” or “We”) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Company’s operating strategies.

MediXall is a technology and innovation-driven organization that has developed a new generation healthcare marketplace platform seeking to address the growing needs of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. The cloud-based MediXall.com platform seeks to connect patients with healthcare providers and wellness services. The Company’s targeted marketplace is Florida, with plans for a nationwide roll-out. Thus far, MediXall has launched the MediXall platform marketplace throughout Florida beginning in 2019 in a controlled launch and launched Health Karma throughout the U.S. in a beta release beginning in August 2020. Further discussion on our operations, mission, and initiatives can be found in the Management’s Discussion and Analysis section of this report.

The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, and (5) Health Karma, Inc. which was established during the third quarter of 2020 to increase functionality of the MediXall platform.

Note 2 – Going Concern

The Company generated no revenue in 2020 and nominal revenue in 2019. The Company has an accumulated deficit of $17,613,510 at September 30, 2020, and does not have sufficient operating cash flows. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

In its report with respect to the Company’s consolidated financial statements for the years ended December 31, 2019 and 2018 as included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 14, 2020, the Company’s independent auditors expressed substantial doubt about the Company’s ability to continue as a going concern. Because the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to September 30, 2020, the Company has issued 703,000 shares of its restricted common stock for total proceeds of $192,000 and issued 660,000 shares of its Series B preferred stock for total proceeds of $660,000.

In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the SEC rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of September 30, 2020 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2020. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on May 14, 2020.

Principles of Consolidation

These condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustment is reflected in current operations.

Subsequent Events

Management has evaluated events occurring subsequent to the condensed consolidated balance sheet date, through November 17, 2020, which is the date the condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 3 - Summary of Significant Accounting Policies, continued

Risks and Uncertainties

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces risk and uncertainty related to the COVID-19 pandemic. Please see Note 8 for further discussion.

Income Taxes

The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of September 30, 2020. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

Revenue Recognition

The Company records revenue when all of the following have occurred; (1) persuasive evidence of an arrangement exists, (2) service delivery has occurred, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.

Revenue is recognized at point of sale, with no further obligations.

Share Based Payment Arrangements

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company fair values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 3 - Summary of Significant Accounting Policies, continued

Loss Per Share

The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive.

Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019:


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2020			2019			2020			2019
Basic and Diluted LPS Computation
Numerator:
Loss available to common stockholders	$	(966,631	)	$	(714,878	)	$	(3,963,726	)	$	(2,129,641	)

Denominator:
Weighted average number of common shares outstanding		93,506,088			74,640,786			88,660,995			72,874,854

Basic and diluted LPS	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.03	)

Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):


Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	3,110,240	—	3,110,240	—

Recent Accounting Pronouncements

On December 18, 2019, the FASB issued Accounting Standards Update (“ASU 2019-12”) “Income taxes (Topic 740)—Simplifying the accounting for income taxes”. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this accounting pronouncement to have a material impact on its condensed consolidated financial statements.

Recoverability of Long-Lived Assets

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the nine month periods ended September 30, 2020 and 2019. However, there can be no assurances that future impairment tests will not result in a charge to operations.

Website and Development Costs

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of September 30, 2020, the Company has met the capitalization requirements and has incurred $427,464 in costs related to the development of the MediXall platform.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 4 – Related Party Transactions

Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG Holdings Corp. (“TBG”) was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Neil Swartz and Timothy Hart are members of the Company’s Board of Directors. Under this agreement, we pay TBG a monthly fee of $40,000. During the three and nine month periods ended September 30, 2020 and 2019, the Company expensed $120,000 and $360,000, respectively, of related party management fees related to this agreement. At September 30, 2020, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $297,630. At December 31, 2019, there are no such prepaid expenses.

R3 Accounting LLC (“R3”), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three and nine month periods ended September 30, 2020 and 2019, the Company expensed $104,050 and $55,725 and $245,050 and $186,275, respectively, related to R3 services.

Prepaid expenses / (Accounts payable and accrued expenses) to related parties are as follows:


Related Party	At September 30, 2020			At December 31, 2019
TBG	$	297,630		$	(241,870	)
R3		(19,931	)		(19,931	)
	$	277,699		$	(261,801	)

EGG Agreement

On September 13, 2019, TurnKey Capital, Inc. (“TurnKey”), a related party of the Company, entered into a Definitive Acquisition Agreement (the “DAA”) with Egg Health Hub, Inc. (“EGG”), pursuant to which EGG would become a wholly owned subsidiary of TurnKey. EGG has no employees, does not currently conduct operations and has no financial assets and liabilities.

EGG is a brand new model for healthcare and wellness that brings together top physicians and wellness professionals into co-practicing communities with shared access to a full-stack technology platform – scheduling, billing, client acquisition, and telemedicine – and flexible access to office space designed to optimize both the physician and client experience. This model creates a compelling new option for re-tenanting traditional shopping centers and mixed-use space.

On July 27, 2020, the Company and TurnKey entered into an assignment of the DAA. As a result of the COVID-19 outbreak, TurnKey determined that the original opportunity that existed with EGG was no longer practical in the short-term. The Company and TurnKey believed, however, that the EGG concept remained a viable concept on a virtual basis, and the Company possesses the infrastructure and willingness to pursue this opportunity. In exchange for 1,000,000 shares of the Company’s common stock, TurnKey assigned its interest in the DAA to the Company. The transaction was accounted for at historical cost as a transaction under common ownership that lacks commercial substance. As such, the issuance of the Company’s common stock to Turnkey was recorded as an increase of $1,000 to common stock, with a corresponding decrease to additional paid-in capital.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 5 – Long Term Debt

During May 2020, the Company received a Paycheck Protection Program (“PPP”) loan in the amount of $165,719. The loan matures in May 2022 and bears an interest rate of 1%. Monthly payments on the loan are deferred until October 2021. The Small Business Administration will forgive the loan if certain employee retention criteria are met and the proceeds are used for eligible expenses.

Note 6 – Preferred Stock

The 264,894 outstanding Series A preferred shares are convertible into 24,900,000 common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion.

On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with 4,000,000 shares authorized for issuance.

Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation.

(a) Automatic Conversion

Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).

(b) Optional Conversion

A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 6 – Preferred Stock, continued

Dividends

Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At September 30, 2020, cumulative unpaid dividends on the Series B Preferred Stock amounted to $13,106.

Voting Rights

Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

Note 7 – Pending Legal Matters

The Company has received a Subpoena from the SEC requesting certain documents in connection with an investigation styled, “In the Matter of TBG Holdings Corporation”. This investigation is a non-public, fact-finding inquiry and does not require disclosure by the Company. The Company has decided to disclose this matter in order to more fully keep our shareholders apprised of matters affecting the Company and its shareholders. The investigation in no way has made a conclusion that anyone has violated any securities laws or regulations. Also, this investigation does not mean the SEC has a negative opinion of any person, entity, or security. All SEC investigations are conducted privately.

TBG Holdings Corp. (“TBG”) is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and Chairman of the Board, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer, Treasurer, Secretary and director, and a significant stockholder of the Company. Messrs. Swartz and Hart are members of the Company’s Board of Directors. Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. Under this agreement, the Company pays TBG a monthly fee of $40,000. As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3 Accounting LLC (“R3”) and other entities. R3, owned by Mr. Hart, provides accounting, tax, and bookkeeping services to the Company.

All transactions between the Company and each of TBG and R3 are routinely updated and disclosed in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, each as filed with the SEC. These filings can be found on the SEC’s public web site at https://www.sec.gov/cgi-bin/browse-edgar?CIK=1601280&owner=exclude.

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC.

Various legal claims arise from time to time in the normal course of business which, in the opinion of management, will not have a material effect on the Company's condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 8 – COVID 19 Pandemic

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 Outbreak”). In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 Outbreak continues to evolve. The impact of the COVID-19 Outbreak on the Company’s results of operations, financial position and cash flows will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 Outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results of operations, financial position and cash flows may be materially adversely affected.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” negatives thereof or similar expressions. Forward-looking statements contained in this report speak only as of the date of this report, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, matters associated with:


	·	our ability to continue as a going concern,
	·	our history of losses which we expect to continue,
	·	the significant amount of liabilities due to related parties,
	·	our ability to raise sufficient capital to fund our company,
	·	our ability to integrate acquisitions and the operations of acquired companies,
	·	the limited experience of our management in the operations of a public company,
	·	potential weaknesses in our internal control over financial reporting,
	·	increased costs associated with reporting obligations as a public company,
	·	a limited market for our common stock and limitations resulting from our common stock being designated as a penny stock,
	·	the ability of our board of directors to issue preferred stock without the consent of our stockholders,
	·	our management controls the voting of our outstanding securities,
	·	the conversion of shares of Series A preferred stock will be very dilutive to our existing common stockholders,
	·	risks associated with and unique to health care,
	·	risks associated with stability of the internet, data security, exposure to data breach, and
	·	risks associated with COVID-19

You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements, including those made in this report, in Part I. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission. Other sections of this report include additional factors which could adversely impact our business and financial performance. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.

OTHER PERTINENT INFORMATION

Unless specifically set forth to the contrary, when used in this report the terms “MediXall Group”, the “Company,” “we”, “us”, “our” and similar terms refer to MediXall Group, Inc., a Nevada corporation, and its wholly-owned subsidiaries.

GENERAL

The following Management’s Discussion and Analysis (“MD&A”) is intended to help the reader understand the Company’s results of operations and financial condition. The MD&A is provided as a supplement to, and should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q.

The MD&A is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

OVERVIEW

MediXall is a technology and innovation-driven organization that is developing a new generation healthcare marketplace platform seeking to address the growing needs of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. The cloud-based MediXall.com platform seeks to connect patients with healthcare providers and wellness services. The Company’s targeted marketplace is Florida, with plans for a nationwide roll-out.

MediXall seeks to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. By approaching the healthcare ecosystem as a whole, MediXall seeks to create, invest and incubate companies that embody its mission statement.

Recent Development

The Company is expanding its MediXall platform to include Health Karma. Health Karma™ is planned to be an end-to-end free healthcare navigation platform that helps consumers make simpler, smarter healthcare decisions regardless of health insurance status. Health Karma will offer an information driven solution that pairs transparency with personalization to deliver smarter savings at every turn, enabling users to get the most from their health insurance plan.

Thus far, MediXall has launched the MediXall platform marketplace throughout Florida beginning in 2019 in a controlled launch and launched Health Karma throughout the U.S. in a beta release beginning in August 2020.

Going Concern

We have incurred net losses of approximately $17.6 million since inception through September 30, 2020. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2019 contains an explanatory paragraph regarding our ability to continue as a going concern based upon the fact that we are dependent upon our ability to increase revenues along with raising additional external capital as needed. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company.

Results of Operations

Three Month Period Ended September 30, 2020 Compared to the Three Month Period Ended September 30, 2019

Revenue

We had no revenue for the three months ended September 30, 2020 and nominal revenue for the three months ended September 30, 2019.

Operating Expenses

A summary of our operating expense for the three month periods ended September 30, 2020 and 2019 follows:


	Three Months Ended
	September 30,				Increase /
	2020		2019		(Decrease)
Operating expense
Professional fees	$	241,454	$	131,988	$	109,466
Professional fees – related party		104,050		55,725		48,325
Management fee – related party		120,000		120,000		—
Personnel related expenses		428,633		311,556		117,077
Other selling, general, and administrative		72,494		96,416		(23,922	)
Total operating expense	$	966,631	$	715,685	$	250,946

Operating expenses increased $250,946, or 35%, to $966,631 during the three months ended September 30, 2020 compared to $715,685 during the same period in 2019. The increase in total operating expenses is primarily due to:


	(1)	An increase in professional fees of $109,466 which primarily resulted from the Company incurring increased legal and consulting fees related to its healthcare platform and the Health Karma anticipated launch.

	(2)	Professional fees-related party increased during the three months ended September 30, 2020 due to increased work performed by R3, related to COVID-19 relocation, amended S-1 registration statement, issuance of the PPP loan and the Series B preferred stock.

	(3)	The increase in personnel related expenses of $117,077 primarily resulted from the Company increasing the development team used in creating the Health Karma platform.

We expect expenses to continue to increase as we move forward with further enhancing the platform.

Nine Month Period Ended September 30, 2020 Compared to the Nine Month Period Ended September 30, 2019

Revenue

We had no revenue for the nine months ended September 30, 2020 and nominal revenue for the nine months ended September 30, 2019.

Operating Expenses

A summary of our operating expense for the nine month periods ended September 30, 2020 and 2019 follows:


	Nine Months Ended
	September 30,				Increase /
	2020		2019		(Decrease)
Operating expense
Professional fees	$	1,145,895	$	448,812	$	697,083
Professional fees – related party		245,050		186,275		58,775
Management fee – related party		360,000		360,000		—
Personnel related expenses		1,998,460		868,602		1,129,858
Other selling, general, and administrative		214,321		268,205		(53,884)
Total operating expense	$	3,963,726	$	2,131,894	$	1,831,832

Operating expenses increased $1,831,832, or 86%, to $3,963,726 during the nine months ended September 30, 2020 compared to $2,131,894 during the same period in 2019. The increase in total operating expenses is primarily due to:


	(1)	An increase in professional fees of $697,083 which primarily resulted from the Company issuing 2,114,375 shares of its restricted common stock for consulting services. The restricted common stock issued had an aggregate fair market value of $548,774.

	(2)	The increase in personnel related expenses of $1,129,858 primarily resulted from the Company issuing 3,730,000 shares of its restricted common stock for employee services. The restricted common stock issued had an aggregate fair market value of $964,291.

We expect expenses to continue to increase as we move forward with further enhancing the platform.

Liquidity and capital resources

Liquidity is the ability of a company to generate sufficient cash to satisfy its needs. At September 30, 2020, we had $519,451 in cash and net working capital of $383,204.

For the nine month period ended September 30, 2020, we raised $2,009,250 from sales of our restricted common stock, net of offering costs of $3,000, and for the nine month period ended September 30, 2019, we raised $1,632,501, net of offering cost of $0. For the nine month period ended September 30, 2020, we raised $777,561 from sales of Series B preferred stock. There were no such sales for the nine month period ended September 30, 2019.

For the nine month period ended September 30, 2020, we received $165,719 from the issuance of long term debt (discussed in Note 5). There were no such issuances for the nine month period ended September 30, 2019.

Net cash used in operating activities for nine month period ended September 30, 2020 was $2,799,664, as compared to $1,769,176 for the nine month period ended September 30, 2019. This change primarily results from our increased net loss, offset by fluctuations in prepaid expenses – related party, accounts payable and accrued expenses, accounts payable and accrued expenses-related party and the issuance of common stock for services rendered.

Our primary source of capital to develop and implement our business plan has been from sales of common and preferred stock.

Other Contractual Obligations

None.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Critical Accounting Policies

Use of Estimates

Risks and Uncertainties

Share Based Payment Arrangements

Recoverability of Long-Lived Assets

Website and Development Costs

Recently Issued Accounting Pronouncements

See Note 3 to our condensed consolidated financial statements for more information regarding recent accounting pronouncements and their impact to our condensed consolidated results of operations and financial position.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

ITEM 4.

CONTROLS AND PROCEDURES.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We carried out an evaluation as required by paragraph (b) of Rule 13a-15 and 15d-15 of the Exchange Act, under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2020.

A material weakness can be defined as an insufficiency of internal controls that may result in a more than remote likelihood that a material misstatement will not be prevented, detected or corrected in a company’s condensed consolidated financial statements.

Based upon that evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2020, our disclosure controls and procedures were not effective, based on the following deficiencies:


	·	Weaknesses in accounting and finance personnel: We have a small accounting staff and we do not have the robust employee resources and expertise needed to meet complex and intricate GAAP and SEC reporting requirements of a U.S. public company. Additionally, numerous adjustments and proposed adjustments have been noted by our auditors. This is deemed by management to be a material weakness in preparing condensed consolidated financial statements.

	·	We have written accounting policies and control procedures, but we do not have sufficient staff to implement the related controls. Management had determined that this lack of the implantation of segregation of duties, as required by our written procedures, represents a material weakness in our internal controls.

	·	Internal control has as its core a basic tenant of segregation of duties. Due to our limited size and economic constraints, the Company is not able to segregate for control purposes various asset control and recording duties and functions to different employees. This lack of segregation of duties had been evaluated by management, and has been deemed to be a material control deficiency.

The Company has determined that the above internal control weaknesses and deficiencies could result in a reasonable possibility for the condensed consolidated financial statements that a material misstatement will not be prevented or detected on a timely basis by the Company’s internal controls.

Management is currently evaluating what steps can be taken in order to address these material weaknesses. As a growing small business, the Company continuously devotes resources to the improvement of our internal control over financial reporting. Due to budget constraints, the staffing size, proficiency and specific expertise in the accounting department is below requirements for the operation. The Company is anticipating correcting deficiencies as funds become available.

Changes in Internal Control Over Financial Reporting

There were no changes during our last fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC.

From time to time, the Company may be the subject of pending or threatened legal actions and proceedings, including those that arise in the ordinary course of business. Management is not aware of any material pending legal proceedings, other than ordinary routine litigation incidental to the business, or proceedings known to be contemplated by governmental authorities, to which the Company or any of its subsidiaries is a party or of which any of their property is the subject. As of the date of this Quarterly Report on Form 10-Q, there are no material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or any associate of any such director, officer, affiliate of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries.

ITEM 1A.

RISK FACTORS.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the nine month period ended September 30, 2020, we:


	·	Received proceeds of $2,009,250, net of offering costs of $3,000, pursuant to a Private Placement Memorandum and for which 8,011,000 shares of restricted common stock were issued. These securities were issued pursuant to exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof.

	·	Received proceeds of $777,561, net of offering costs of $0, pursuant to a Private Placement Memorandum and for which 777,560 shares of restricted Series B preferred stock were issued. These securities were issued pursuant to exemptions from the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof.

	·	Issued 5,844,375 restricted shares of common stock as compensation for services rendered by employees, advisors and independent contractors of the Company with a fair market value of $1,513,065. These securities were issued pursuant to exemptions from the registration requirements of the Securities Act, pursuant to Section 4(a)(2) thereof.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.

MINE SAFETY DISCLOSURES.

Not applicable to our Company.

ITEM 5.

OTHER INFORMATION.

None.

ITEM 6.

EXHIBITS.


Exhibit No.		Description
10.1		Consulting Agreement dated as of July 1, 2019 by and between MediXall Group, Inc. and TBG Holdings Corporation. *
31.1		Rule 13a-14(a)/ 15d-14(a) Certification of Interim Chief Executive Officer *
31.2		Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer *
32.1		Section 1350 Certification of Interim Chief Executive Officer *
32.2		Section 1350 Certification of Chief Financial Officer *
101.INS		XBRL Instance Document *
101.SCH		XBRL Taxonomy Extension Schema *
101.CAL		XBRL Taxonomy Extension Calculation Linkbase *
101.DEF		XBRL Taxonomy Extension Definition Linkbase *
101.LAB		XBRL Taxonomy Extension Label Linkbase *
101.PRE		XBRL Taxonomy Extension Presentation Linkbase *

———————

Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	MediXall Group, Inc.

Dated: November 17, 2020	By:	/s/ Timothy S. Hart
		Timothy S. Hart
		Chief Financial Officer (Principal Financial and Accounting Officer)


Dated: November 17, 2020	By:	/s/ Neil Swartz
		Neil Swartz
		Interim Chief Executive Officer (Principal Executive Officer)

EX-10.1 2 mdxl_ex10z1.htm CONSULTING AGREEMENT Consulting Agreement

EXHIBIT 10.1

[mdxl_ex10z1001.jpg]

CONSULTING AGREEMENT

This Consulting Agreement (the “Agreement”) is made as of July 1, 2019 (the “Effective Date”) by and between MediXall Group, Inc., a corporation organized under the laws of the State of Nevada, with its principal place of business at 2929 E. Commercial Blvd., PH-D, Ft. Lauderdale, FL 33308, (the “Company”), and TBG Holdings Corporation, a corporation organized under the laws of the State of Florida, with its principal place of business at 2929 E. Commercial Blvd., PH-D, Ft. Lauderdale, FL 33308, (the “Consultant”). This Agreement supersedes all Agreement executed prior to the effective date identified above, by and between TBG Holdings Corporation and MediXall Group, Inc. f/k/a Continental Rail Corp.

WHEREAS, Consultant has extensive experience and expertise in creating and building public companies, corporate strategic planning, financial strategy, and market awareness; and

WHEREAS, the Company desires to engage the services of Consultant and Consultant desires to provide such consulting services to the Company as an independent contractor on such matters within the experience and expertise of the Consultant, under the terms and conditions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, receipt of which is hereby acknowledged, the parties agree as follows:

Consulting Services

1.1.

Consultant shall provide the Company with the services as follows:

Consultant agrees, to the best of his knowledge and ability, to advise the Company regarding financial matters, financial strategy, corporate strategic planning and public market awareness and to provide such other services as agreed by both parties.

1.2.

Consultant undertakes to perform his duties and obligations under this Agreement with the highest degree of professionalism and shall abide by all laws, rules and regulations that apply to the performance of the Consulting Services.

TBG Holdings Corp. l 2929 E. Commercial Blvd, PH-D, Ft. Lauderdale, FL 33308 l 954-440-4678

Status of Parties

Consultant shall at all times act as an independent contractor and not as an employee of the

Company and shall not have authority to speak for, represent, obligate or legally bind the Company in any way.

Term of the Agreement

The term of this Agreement is 12 months. The Agreement may be terminated by the Company 180 days from execution hereof.

Fees and Expenses

4.1.

In consideration of Consultant's obligations under this Agreement, certain affiliates of the Company shall pay Consultant the following:

(a)

The Company shall immediately deliver a consulting fee of $40,000.00 for Month 1, and $40,000.00 per month thereafter.

(b)

TBG Holdings Corporation will receive an agreed-upon consulting fee for all introductions made to the Company.

4.2.

All fees to TBG Holdings Corporation will be accrued and paid, once new funds come into the Company and existing management starts being paid.

Reporting

Consultant’s Services with respect to this Agreement shall be coordinated with the Company through the Company’s Chief Executive Officer, Chief Operating Officer or Chairman of the Board, or their respective designees from time to time.

Confidentiality and Proprietary Rights

As a basic condition to entering into this Agreement, Consultant warrants and undertakes to execute, be bound by and comply with the Confidentiality and Proprietary Rights as requested by the Company.

Covenants, Representations and Warranties

Both parties represent and warrant that the execution of this Agreement will not violate, breach or otherwise conflict with any term or provision of any contract or agreement, written or oral, to which either party is a party thereto.

TBG Holdings Corp. l 2929 E. Commercial Blvd, PH-D, Ft. Lauderdale, FL 33308 l 954-440-4678

General

8.1.

Neither party hereto shall assign any of its rights and obligations hereunder without the prior written consent of the other party.

8.2.

Either party's failure at any time to require strict compliance by the other party of the provisions of this Agreement shall not diminish such party's right thereafter to demand strict compliance therewith or with any other provision. Waiver of any particular default shall not waive any other default.

8.3.

All disputes with respect to this Agreement shall be determined in accordance with the laws of the State of Florida.

8.4.

In the event that any provision of this Agreement shall be deemed unlawful or otherwise unenforceable, such provision shall be severed from this Agreement and the balance of the Agreement shall continue in full force and effect.

8.5.

This Agreement contains and sets forth the entire agreement and understanding between the parties with respect to the subject matter contained herein, and such supersedes all prior discussions, agreements, representations and understandings in this regard. This Agreement shall not be modified except by an instrument in writing signed by both parties.

8.6.

Any notice permitted, required or desired to be given under this Agreement shall be in writing, fax or via email and shall be deemed to have been effectively given when delivered to the party (i) if personally delivered, or (ii) if sent via email or facsimile, upon successful transmission to:

In the case of the Company:

MediXall Group, Inc.

2929 E. Commercial Blvd., PH-D

Ft. Lauderdale, FL 33308

Attention: Timothy Hart

In the case of the Consultant:

TBG Holdings Corporation

2929 E. Commercial Blvd., PH-D

Ft. Lauderdale, FL 33308

Attention: Neil Swartz

or to such address as may have been designated by the Company or the Consultant.

TBG Holdings Corp. l 2929 E. Commercial Blvd, PH-D, Ft. Lauderdale, FL 33308 l 954-440-4678

IN WITNESS WHEREOF, the duly authorized representatives of the Company and Consultant have executed this Agreement as of the date stated below.


COMPANY:		CONSULTANT:

MediXall Group, Inc.		TBG Holdings Corporation


/s/ Timothy Hart		/s/ Neil Swartz
Timothy Hart, CFO		Neil Swartz, CEO

TBG Holdings Corp. l 2929 E. Commercial Blvd, PH-D, Ft. Lauderdale, FL 33308 l 954-440-4678

EX-31.1 3 mdxl_ex31z1.htm CERTIFICATION Certification

EXHIBIT 31.1

CERTIFICATIONS

I, Neil Swartz, certify that:


1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2020 of MediXall Group, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 17, 2020


	/s/ Neil Swartz
	Neil Swartz
	Interim Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 4 mdxl_ex31z2.htm CERTIFICATION Certification

EXHIBIT 31.2

CERTIFICATIONS

I, Timothy S. Hart, certify that:


1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2020 of MediXall Group, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 17, 2020


	/s/ Timothy S. Hart
	Timothy S. Hart
	Chief Financial Officer
	(Principal Financial Officer)

EX-32.1 5 mdxl_ex32z1.htm CERTIFICATION Certification

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Neil Swartz, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: November 17, 2020	/s/ Neil Swartz
	Neil Swartz
	Interim Chief Executive Officer
	(Principal Executive Officer)

EX-32.2 6 mdxl_ex32z2.htm CERTIFICATION Certification

EXHIBIT 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy S. Hart, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: November 17, 2020	/s/ Timothy S. Hart
	Timothy S. Hart
	Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 7 mdxl-20200930.xml XBRL INSTANCE FILE 0001601280 2019-12-31 0001601280 2020-09-30 0001601280 2020-01-01 2020-09-30 0001601280 2020-11-17 0001601280 mdxl:TBGHoldingsCorpMember 2020-09-30 0001601280 mdxl:R3AccountingLLCMember 2020-09-30 0001601280 mdxl:TBGHoldingsCorpMember 2019-12-31 0001601280 mdxl:R3AccountingLLCMember 2019-12-31 0001601280 mdxl:TBGHoldingsCorpMember 2020-07-01 2020-09-30 0001601280 mdxl:TBGHoldingsCorpMember 2019-07-01 2019-09-30 0001601280 mdxl:TBGHoldingsCorpMember 2019-01-01 2019-09-30 0001601280 mdxl:TBGHoldingsCorpMember 2013-09-29 2013-09-30 0001601280 mdxl:R3AccountingLLCMember 2020-07-01 2020-09-30 0001601280 mdxl:R3AccountingLLCMember 2019-07-01 2019-09-30 0001601280 mdxl:R3AccountingLLCMember 2019-01-01 2019-09-30 0001601280 us-gaap:PreferredStockMember 2018-12-31 0001601280 us-gaap:CommonStockMember 2018-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001601280 us-gaap:RetainedEarningsMember 2018-12-31 0001601280 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001601280 us-gaap:PreferredStockMember 2019-06-30 0001601280 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001601280 us-gaap:CommonStockMember 2019-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001601280 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001601280 us-gaap:RetainedEarningsMember 2019-06-30 0001601280 2019-07-01 2019-09-30 0001601280 mdxl:TBGHoldingsCorpMember 2020-01-01 2020-09-30 0001601280 mdxl:R3AccountingLLCMember 2020-01-01 2020-09-30 0001601280 us-gaap:PreferredStockMember 2019-09-30 0001601280 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001601280 us-gaap:CommonStockMember 2019-09-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001601280 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001601280 us-gaap:RetainedEarningsMember 2019-09-30 0001601280 2019-09-30 0001601280 2019-01-01 2019-09-30 0001601280 us-gaap:PreferredStockMember 2019-03-31 0001601280 us-gaap:CommonStockMember 2019-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001601280 us-gaap:RetainedEarningsMember 2019-03-31 0001601280 2019-06-30 0001601280 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001601280 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001601280 2019-04-01 2019-06-30 0001601280 2018-12-31 0001601280 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001601280 us-gaap:PreferredStockMember 2019-12-31 0001601280 us-gaap:PreferredStockMember 2020-06-30 0001601280 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001601280 us-gaap:CommonStockMember 2019-12-31 0001601280 us-gaap:CommonStockMember 2020-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001601280 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001601280 us-gaap:RetainedEarningsMember 2019-12-31 0001601280 us-gaap:RetainedEarningsMember 2020-06-30 0001601280 2020-07-01 2020-09-30 0001601280 us-gaap:PreferredStockMember 2020-09-30 0001601280 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001601280 us-gaap:CommonStockMember 2020-09-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001601280 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001601280 us-gaap:RetainedEarningsMember 2020-09-30 0001601280 2020-06-30 0001601280 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001601280 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001601280 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001601280 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2020-07-01 2020-09-30 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2018-12-31 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2019-06-30 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2019-09-30 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2019-12-31 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2020-06-30 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2020-09-30 0001601280 2020-01-01 2020-03-31 0001601280 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-09-30 0001601280 us-gaap:SeriesAPreferredStockMember 2020-07-01 2020-09-30 0001601280 us-gaap:SeriesAPreferredStockMember 2019-07-01 2019-09-30 0001601280 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-09-30 0001601280 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-09-30 0001601280 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-09-30 0001601280 us-gaap:SeriesBPreferredStockMember 2019-07-01 2019-09-30 0001601280 us-gaap:SeriesBPreferredStockMember 2020-07-01 2020-09-30 0001601280 2019-01-01 2019-03-31 0001601280 2020-07-27 0001601280 us-gaap:PreferredStockMember 2020-03-31 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2020-04-01 2020-06-30 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2020-03-31 0001601280 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001601280 us-gaap:CommonStockMember 2020-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001601280 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001601280 us-gaap:RetainedEarningsMember 2020-03-31 0001601280 2020-04-01 2020-06-30 0001601280 2020-03-31 0001601280 mdxl:ConvertiblePreferredStockSeriesBMember 2019-03-31 0001601280 2019-03-31 0001601280 us-gaap:SubsequentEventMember us-gaap:SeriesBPreferredStockMember 2020-10-01 2020-11-16 0001601280 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember 2020-10-01 2020-11-16 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

0.001

750000000

264894

777560

2020-09-30 Q3 --12-31 10-Q 0001601280 false 2020 MediXall Group, Inc. Yes 360000 120000 120000 360000 120000 360000 360000 120000

80952555

95807930

Non-accelerated Filer false true 96510930

-3963726

-744398

-714878

-2129641

-670365

-1851085

-966631

-1851085

-744398

-1146010

245050 104050 55725 186275 55725 245050 186275 104050

2009250

1632501

660000

192000

277560

500000

660000

703000

261801

19931

241870

19931

40000 24900000 true Yes 333-194337 NV

80952555

95807930

540220

599596

46277

493943

433877

71362

65457

160780

348489

937980

1333506

356704

427464

113395

61425

21662

27536

446219

817081

80953

95808

13966326

18250569

-13649784

-17613510

937980

1333506

88660995

74640786

72874854

93506088

-0.04

-0.01

-0.03

-0.01

-3963726

-714878

-2129641

-966631

3963726

715685

2131894

966631

214321

96416

268205

72494

1998460

311556

868602

428633

1145895

131988

448812

241454

807

2253

-2799664

-1769176

52182 44991

51970

49047

-241870

20319

187709

51166

1513065

121334

3000

8874

8880

70760

5247

-79634

-14127

446219

519451

50707

201509

30000

179341

73232

-150802

165719

265

778

1000000

4000000

264894

777560

777561

165719

2952530

1632501

24900000

3110240

165719

0.01

2022-05-31

0.08

1000000

13106

397760

733910

265

69642

10701887

-10228833

265

73705

11822325

-11643596

265

75469

12479895

-12358474

197155

265

72233

11432170

-10973231

252699

542961

265

80953

91054

13966326

17067540

-13649784

-16646879

265

95808

18250569

-17613510

512480

500

778

265

86824

15505270

-15500869

91490

531437

264894

69642554

264894

73705054

264894

75468722

264894

72233554

264894

80952555

91053930

264894

95807930

500000

777560

264894

86823930

2351

605523

633000

1711

631289

1472

390155

391627

1907

499843

910500

3754

906746

501750

607874

2350

594650

597000

2351000

1711000

1471500

1907000

3754000

2350000

240

124760

26334

26281

3964

1039101

1043065

125000

1880

468120

470000

240000

52668

3964375

1880000

277561

277283

278

500

499500

500000

1000 -1000 1000000

3000

1000

Note 2 Going Concern The Company generated no revenue in 2020 and nominal revenue in 2019. The Company has an accumulated deficit of $17,613,510 at September 30, 2020, and does not have sufficient operating cash flows. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (GAAP), which contemplates continuation of the Company as a going concern, which is dependent upon the Companys ability to establish itself as a profitable business. In its report with respect to the Companys consolidated financial statements for the years ended December 31, 2019 and 2018 as included in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on May 14, 2020, the Companys independent auditors expressed substantial doubt about the Companys ability to continue as a going concern. Because the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to September 30, 2020, the Company has issued 703,000 shares of its restricted common stock for total proceeds of $192,000 and issued 660,000 shares of its Series B preferred stock for total proceeds of $660,000. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying condensed consolidated financial statements.

Note 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the SEC rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Companys condensed consolidated financial position as of September 30, 2020 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2020. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the Companys Annual Report on Form 10-K, which was filed with the SEC on May 14, 2020. Principles of Consolidation These condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustment is reflected in current operations. Subsequent Events Management has evaluated events occurring subsequent to the condensed consolidated balance sheet date, through November 17, 2020, which is the date the condensed consolidated financial statements were issued, determining all subsequent events have been disclosed. Risks and Uncertainties The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces risk and uncertainty related to the COVID-19 pandemic. Please see Note 8 for further discussion. Income Taxes The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Boards (FASB) Accounting Standards Codification  740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of September 30, 2020. Accordingly, a valuation allowance was recorded against the net deferred tax asset. Revenue Recognition The Company records revenue when all of the following have occurred; (1) persuasive evidence of an arrangement exists, (2) service delivery has occurred, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured. Revenue is recognized at point of sale, with no further obligations. Share Based Payment Arrangements The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company fair values the stock-based compensation at the market price for the Company's stock as of the date of issuance. Loss Per Share The computation of basic loss per share (LPS) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive. Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.66px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="6" style="margin-top: 0px; vertical-align: bottom; width: 161.33px">Three Months Ended </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="6" style="margin-top: 0px; vertical-align: bottom; width: 161.33px">Nine Months Ended </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="6" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 161.33px">September 30, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="6" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 161.33px">September 30, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Basic and Diluted LPS Computation </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Numerator: </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Loss available to common stockholders </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(966,631 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(714,878 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(3,963,726 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(2,129,641 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Denominator: </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Weighted average number of common shares outstanding </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">93,506,088 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">74,640,786 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">88,660,995 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">72,874,854 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Basic and diluted LPS </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.01 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.01 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.04 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.03 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td></tr> </table> Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.66px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Series A Preferred stock (convertible) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Series B Preferred stock (convertible) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">3,110,240 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">3,110,240 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> </table> Recent Accounting Pronouncements On December 18, 2019, the FASB issued Accounting Standards Update (ASU 2019-12) Income taxes (Topic 740)Simplifying the accounting for income taxes. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this accounting pronouncement to have a material impact on its condensed consolidated financial statements. Recoverability of Long-Lived Assets The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the nine month periods ended September 30, 2020 and 2019. However, there can be no assurances that future impairment tests will not result in a charge to operations. Website and Development Costs   Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of September 30, 2020, the Company has met the capitalization requirements and has incurred $427,464 in costs related to the development of the MediXall platform.

Note 4 Related Party Transactions Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG Holdings Corp. (TBG) was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Companys Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Companys Chief Financial Officer and director, and a significant stockholder of the Company. Neil Swartz and Timothy Hart are members of the Companys Board of Directors. Under this agreement, we pay TBG a monthly fee of $40,000. During the three and nine month periods ended September 30, 2020 and 2019, the Company expensed $120,000 and $360,000, respectively, of related party management fees related to this agreement. At September 30, 2020, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $297,630. At December 31, 2019, there are no such prepaid expenses. R3 Accounting LLC (R3), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three and nine month periods ended September 30, 2020 and 2019, the Company expensed $104,050 and $55,725 and $<a name="Hlk46655441"></a>245,050 and $186,275, respectively, related to R3 services. Prepaid expenses / (Accounts payable and accrued expenses) to related parties are as follows: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6px"></td><td style="width: 6.66px"></td><td style="width: 69px"></td><td style="width: 7.8px"></td><td style="width: 11px"></td><td style="width: 6.66px"></td><td style="width: 69px"></td><td style="width: 6px"></td></tr> <tr><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom">Related Party </td><td style="margin-top: 0px; vertical-align: bottom; width: 6px">  </td><td colspan="2" style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 75.66px">At September 30, 2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 7.8px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 11px">  </td><td colspan="2" style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 75.66px">At December 31, 2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: top">TBG </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">297,630 </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 7.8px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 11px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">(241,870 </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">) </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: top">R3 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69px">(19,931 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 7.8px">)  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 11px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69px">(19,931 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6px">) </td></tr> <tr><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: top">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">277,699 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 7.8px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 11px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">(261,801 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">) </td></tr> </table> EGG Agreement On September 13, 2019, TurnKey Capital, Inc. (TurnKey), a related party of the Company, entered into a Definitive Acquisition Agreement (the DAA) with Egg Health Hub, Inc. (EGG), pursuant to which EGG would become a wholly owned subsidiary of TurnKey. EGG has no employees, does not currently conduct operations and has no financial assets and liabilities. EGG is a brand new model for healthcare and wellness that brings together top physicians and wellness professionals into co-practicing communities with shared access to a full-stack technology platform scheduling, billing, client acquisition, and telemedicine and flexible access to office space designed to optimize both the physician and client experience. This model creates a compelling new option for re-tenanting traditional shopping centers and mixed-use space. On July 27, 2020, the Company and TurnKey entered into an assignment of the DAA. As a result of the COVID-19 outbreak, TurnKey determined that the original opportunity that existed with EGG was no longer practical in the short-term. The Company and TurnKey believed, however, that the EGG concept remained a viable concept on a virtual basis, and the Company possesses the infrastructure and willingness to pursue this opportunity. In exchange for 1,000,000 shares of the Companys common stock, TurnKey assigned its interest in the DAA to the Company. The transaction was accounted for at historical cost as a transaction under common ownership that lacks commercial substance. As such, the issuance of the Companys common stock to Turnkey was recorded as an increase of $1,000 to common stock, with a corresponding decrease to additional paid-in capital.

Note 5 Long Term Debt During May 2020, the Company received a Paycheck Protection Program (PPP) loan in the amount of $165,719. The loan matures in May 2022 and bears an interest rate of 1%.  Monthly payments on the loan are deferred until October 2021. The Small Business Administration will forgive the loan if certain employee retention criteria are met and the proceeds are used for eligible expenses.

Note 6 Preferred Stock The 264,894 outstanding Series A preferred shares are convertible into 24,900,000 common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion. On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the Secretary of State) a certificate of designation (the Certificate of Designation) of Series B Convertible Preferred Stock, par value $0.001 per share (the Series B Preferred Stock). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with 4,000,000 shares authorized for issuance.   Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the Conversion Ratio) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the Conversion Shares) as set forth in the Certificate of Designation.   (a)       Automatic Conversion   Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a Series B Holder and collectively, Series B Holders).   (b)       Optional Conversion   A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation. Dividends Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the Series B Dividend). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the Stock Dividend). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At September 30, 2020, cumulative unpaid dividends on the Series B Preferred Stock amounted to $13,106. Voting Rights   Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Companys common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

Note 8 COVID 19 Pandemic On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus (the COVID-19 Outbreak). In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 Outbreak continues to evolve. The impact of the COVID-19 Outbreak on the Companys results of operations, financial position and cash flows will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 Outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Companys results of operations, financial position and cash flows may be materially adversely affected.

Basis of Presentation The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the SEC rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Companys condensed consolidated financial position as of September 30, 2020 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2020. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the Companys Annual Report on Form 10-K, which was filed with the SEC on May 14, 2020.

Principles of Consolidation These condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustment is reflected in current operations.

Subsequent Events Management has evaluated events occurring subsequent to the condensed consolidated balance sheet date, through November 16, 2020, which is the date the condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

Risks and Uncertainties The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces risk and uncertainty related to the COVID-19 pandemic. Please see Note 8 for further discussion.

Income Taxes The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Boards (FASB) Accounting Standards Codification  740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of September 30, 2020. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

Revenue Recognition The Company records revenue when all of the following have occurred; (1) persuasive evidence of an arrangement exists, (2) service delivery has occurred, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured. Revenue is recognized at point of sale, with no further obligations.

Share Based Payment Arrangements The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company fair values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

Loss Per Share The computation of basic loss per share (LPS) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive. Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.66px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="6" style="margin-top: 0px; vertical-align: bottom; width: 161.33px">Three Months Ended </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="6" style="margin-top: 0px; vertical-align: bottom; width: 161.33px">Nine Months Ended </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="6" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 161.33px">September 30, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="6" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 161.33px">September 30, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Basic and Diluted LPS Computation </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Numerator: </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Loss available to common stockholders </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(966,631 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(714,878 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(3,963,726 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(2,129,641 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Denominator: </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Weighted average number of common shares outstanding </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">93,506,088 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">74,640,786 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">88,660,995 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">72,874,854 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Basic and diluted LPS </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.01 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.01 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.04 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.03 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td></tr> </table> Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.66px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Series A Preferred stock (convertible) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Series B Preferred stock (convertible) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">3,110,240 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">3,110,240 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px"> </td></tr></table>

Recent Accounting Pronouncements On December 18, 2019, the FASB issued Accounting Standards Update (ASU 2019-12) Income taxes (Topic 740)Simplifying the accounting for income taxes. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles and also improve consistent application by clarifying and amending existing guidance, such as franchise taxes and interim recognition of enactment of tax laws or rate changes. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this accounting pronouncement to have a material impact on its condensed consolidated financial statements.

Recoverability of Long-Lived Assets The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the nine month periods ended September 30, 2020 and 2019. However, there can be no assurances that future impairment tests will not result in a charge to operations.

Website and Development Costs   Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of September 30, 2020, the Company has met the capitalization requirements and has incurred $427,464 in costs related to the development of the MediXall platform.

Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.66px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="6" style="margin-top: 0px; vertical-align: bottom; width: 161.33px">Three Months Ended </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="6" style="margin-top: 0px; vertical-align: bottom; width: 161.33px">Nine Months Ended </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="6" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 161.33px">September 30, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="6" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 161.33px">September 30, </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td colspan="2" style="border-bottom: #000000 1.33px solid; margin-top: 0px; vertical-align: bottom; width: 73.93px">2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Basic and Diluted LPS Computation </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Numerator: </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Loss available to common stockholders </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(966,631 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(714,878 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(3,963,726 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">(2,129,641 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">) </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Denominator: </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Weighted average number of common shares outstanding </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">93,506,088 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">74,640,786 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">88,660,995 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 67.2px">72,874,854 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Basic and diluted LPS </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.01 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.01 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.04 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; vertical-align: bottom; width: 67.2px">(0.03 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; vertical-align: bottom; width: 6.73px">) </td></tr> </table>

Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6.66px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 6.73px"></td><td style="width: 67.2px"></td><td style="width: 6.73px"></td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom">Series A Preferred stock (convertible) </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 67.2px">24,900,000 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.73px">  </td></tr> <tr><td style="margin-top: 0px; vertical-align: bottom">Series B Preferred stock (convertible) </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.66px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">3,110,240 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px"> </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px">3,110,240 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 6.73px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 67.2px"> </td></tr></table>

Accounts receivable / (Accounts payable and accrued expenses) to related parties are as follows: <table cellpadding="0" cellspacing="0" style="margin-top: 0px; font-size: 10pt; width: 100%"><tr style="height: 0px; font-size: 0"><td></td><td style="width: 6px"></td><td style="width: 6.66px"></td><td style="width: 69px"></td><td style="width: 7.8px"></td><td style="width: 11px"></td><td style="width: 6.66px"></td><td style="width: 69px"></td><td style="width: 6px"></td></tr> <tr><td style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom">Related Party </td><td style="margin-top: 0px; vertical-align: bottom; width: 6px">  </td><td colspan="2" style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 75.66px">At September 30, 2020 </td><td style="margin-top: 0px; vertical-align: bottom; width: 7.8px">  </td><td style="margin-top: 0px; vertical-align: bottom; width: 11px">  </td><td colspan="2" style="border-bottom: #000000 1px solid; margin-top: 0px; vertical-align: bottom; width: 75.66px">At December 31, 2019 </td><td style="margin-top: 0px; vertical-align: bottom; width: 6px">  </td></tr> <tr><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: top">TBG </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">297,630 </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 7.8px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 11px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">(241,870 </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">) </td></tr> <tr><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: top">R3 </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69px">(19,931 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 7.8px">)  </td><td style="margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 11px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6.66px">  </td><td style="border-bottom: #000000 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 69px">(19,931 </td><td style="border-bottom: #FFFFFF 1px solid; margin-top: 0px; background-color: #CCFFCC; vertical-align: bottom; width: 6px">) </td></tr> <tr><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: top">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">277,699 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 7.8px">  </td><td style="margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 11px">  </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6.66px">$ </td><td style="border-bottom: #000000 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 69px">(261,801 </td><td style="border-bottom: #FFFFFF 3px double; margin-top: 0px; background-color: #FFFFFF; vertical-align: bottom; width: 6px">) </td></tr> </table>

Note 1 - Organization and Nature of Operation MediXall Group, Inc. (the "Company or MediXall or We) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Companys operating strategies. MediXall is a technology and innovation-driven organization that has developed a new generation healthcare marketplace platform seeking to address the growing needs of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. The cloud-based MediXall.com platform seeks to connect patients with healthcare providers and wellness services. The Companys targeted marketplace is Florida, with plans for a nationwide roll-out. Thus far, MediXall has launched the MediXall platform marketplace throughout Florida beginning in 2019 in a controlled launch and launched Health Karma throughout the U.S. in a beta release beginning in August 2020. Further discussion on our operations, mission, and initiatives can be found in the Managements Discussion and Analysis section of this report. The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, and (5) Health Karma, Inc. which was established during the third quarter of 2020 to increase functionality of the MediXall platform.

Note 7 Pending Legal Matters The Company has received a Subpoena from the SEC requesting certain documents in connection with an investigation styled, In the Matter of TBG Holdings Corporation. This investigation is a non-public, fact-finding inquiry and does not require disclosure by the Company. The Company has decided to disclose this matter in order to more fully keep our shareholders apprised of matters affecting the Company and its shareholders. The investigation in no way has made a conclusion that anyone has violated any securities laws or regulations. Also, this investigation does not mean the SEC has a negative opinion of any person, entity, or security. All SEC investigations are conducted privately. TBG Holdings Corp. (TBG) is owned in part by Neil Swartz, the Companys Interim Chief Executive Officer and Chairman of the Board, and a significant stockholder of the Company, and Timothy Hart, the Companys Chief Financial Officer, Treasurer, Secretary and director, and a significant stockholder of the Company. Messrs. Swartz and Hart are members of the Companys Board of Directors.  Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. Under this agreement, the Company pays TBG a monthly fee of $40,000. As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3 Accounting LLC (R3) and other entities.  R3, owned by Mr. Hart, provides accounting, tax, and bookkeeping services to the Company. All transactions between the Company and each of TBG and R3 are routinely updated and disclosed in the Companys Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, each as filed with the SEC. These filings can be found on the SECs public web site at https://www.sec.gov/cgi-bin/browse-edgar?CIK=1601280&owner=exclude. The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion. To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC. Various legal claims arise from time to time in the normal course of business which, in the opinion of management, will not have a material effect on the Company's condensed consolidated financial statements.

297630

-160590

EX-101.SCH 8 mdxl-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Nature of Operation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders Deficit link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Pending Legal Matters link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COVID 19 Pandemic link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted LPS) (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Pending Legal Matters (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Lease (Schedule of Components of Lease Expense and Other Lease Information) (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Leases (Schedule of Future Minimum Lease Commitments) (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mdxl-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 mdxl-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 mdxl-20200930_lab.xml XBRL LABEL FILE Related Party [Axis] TBG Holdings Corp. [Member] R3Accounting, LLC [Member] Equity Components [Axis] Series A Voting Preferred Stock$0.001 Par Value [Member[ Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Class of Stock [Axis] Convertible Preferred Stock Series A [Member] Convertible Preferred Stock Series B [Member] Series B Voting Preferred Stock $0.001 Par Value [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Restricted Common Stock [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Entity Shell Company Entity Interactive Data Current Entity File Number Entity Incorporation Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS: Cash Prepaid expenses - related party Total current assets Furniture and equipment, net Right-of-use operating lease asset Website and development costs Total assets LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Operating lease liability Total current liabilities Operating lease liability, net of current portion Long term debt Total liabilities Commitment and contingencies STOCKHOLDERS' EQUITY: Convertible Preferred stock Common Stock, $0.001 par value 750,000,000 shares authorized; 95,807,930 and 80,952,555 shares issued and outstanding Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Convertible Preferred stock, par value (in dollars per share) Convertible Preferred stock, shares authorized Convertible Preferred stock, shares issued Convertible Preferred stock, shares outstanding Common Stock, Par value (in dollars per share) Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] Revenue Operating Expenses Professional fees Professional fees - related party Management fee - related party Personnel related expenses Other selling, general and administrative Total Operating Expenses Loss before income taxes Income taxes Net Loss Net loss per common share - basic and diluted Weighted average number of common shares outstanding during the periods - basic and diluted Balance Balance, Shares Proceeds received pursuant to Private Placement Memorandum, net of offering costs Proceeds received pursuant to Private Placement Memorandum, Shares Proceeds received from sale of Preferred Stock Proceeds received from sale of Preferred Stock, Shares Common stock issued for services Common stock issued for services, Shares Common stock issued to related party (unaudited) Common stock issued to related party (unaudited) Shares Net Loss Balance Balance, Shares Statement of Stockholders' Equity [Abstract] Offering costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to cash used in operating activities: Depreciation Stock issued as compensation for services Changes in operating assets and liabilities: Accounts receivable - related party Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Right-of-use operating lease asset Operating lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of furniture and equipment Website development costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from the sale of common stock, net of offering costs Proceeds from the sale of preferred stock Proceeds from long term debt Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid in cash Income taxes paid in cash Non-cash transactions: Reclassification of stock compensation from other liabilities to common stock Right-of-use asset obtained in exchange for operating lease liabilities Common stock issued to related party Organization Going Concern And Summary Of Significant Accounting Policies Organization and Nature of Operation Numerator: Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Stockholders' Equity Note [Abstract] Stockholders Equity Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Long Term Debt Equity [Abstract] Preferred Stock Commitments and Contingencies Disclosure [Abstract] Pending Legal Matters COVID 19 Pandemic Leases [Abstract] Lease Subsequent Events [Abstract] Subsequent Events Basis of Presentation Principles of Consolidation Use of Estimates Subsequent Events Risks and Uncertainties Furniture and Equipment, Net Fair Value Measurement Fair Value of Financial Instruments Income Taxes Revenue Recognition Share Based Payment Arrangements Loss Per Share Recent Accounting Pronouncements Recoverability of Long-Lived Assets Website and Development Costs Schedule of computation of basic and diluted net loss per share Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share Schedule of accounts receivable (accounts payable and accrued expenses) to related parties Schedule of Components of Lease Expense and Other Lease Information Schedule of Maturities of Lease Liabilities Accumulated deficit Stock issued Proceeds from stock issued Basic and Diluted LPS Computation Numerator: Loss available to common stockholders Denominator: Weighted average number of common shares outstanding Basic and diluted LPS Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Preferred stock (convertible) Accounts payable and accrued expenses - related party Due from (to) related party Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Fee for accounting services Management agreement description Monthly management fee Stock issued from EGG to Turnkey Prepaid management fees - related party PPP loan Interest rate Maturity date Convertible Preferred Series A stock, shares authorized Number of common stock issuable for total shares of convertible preferred stock Dividend rate Dividends EX-101.PRE 12 mdxl-20200930_pre.xml XBRL PRESENTATION FILE GRAPHIC 13 mdxl_ex10z1001.jpg GRAPHIC begin 644 mdxl_ex10z1001.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 17, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	MediXall Group, Inc.
Entity Central Index Key	0001601280
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		96,510,930
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Shell Company	true
Entity Interactive Data Current	Yes
Entity File Number	333-194337
Entity Incorporation	NV

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 519,451	$ 446,219
Prepaid expenses - related party	297,630
Total current assets	817,081	446,219
Furniture and equipment, net	27,536	21,662
Right-of-use operating lease asset	61,425	113,395
Website and development costs	427,464	356,704
Total assets	1,333,506	937,980
CURRENT LIABILITIES:
Accounts payable and accrued expenses	348,489	160,780
Accounts payable and accrued expenses - related party	19,931	261,801
Operating lease liability	65,457	71,362
Total current liabilities	433,877	493,943
Operating lease liability, net of current portion		46,277
Long term debt	165,719
Total liabilities	599,596	540,220
STOCKHOLDERS' EQUITY:
Common Stock, $0.001 par value 750,000,000 shares authorized; 95,807,930 and 80,952,555 shares issued and outstanding	95,808	80,953
Additional paid-in capital	18,250,569	13,966,326
Accumulated deficit	(17,613,510)	(13,649,784)
Total stockholders' equity	733,910	397,760
Total liabilities and stockholders' equity	1,333,506	937,980
Convertible Preferred Stock Series A [Member]
STOCKHOLDERS' EQUITY:
Convertible Preferred stock	265	265
Convertible Preferred Stock Series B [Member]
STOCKHOLDERS' EQUITY:
Convertible Preferred stock	$ 778

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Common Stock, Par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	750,000,000	750,000,000
Common Stock, shares issued	95,807,930	80,952,555
Common Stock, shares outstanding	95,807,930	80,952,555
Convertible Preferred Stock Series A [Member]
Convertible Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	1,000,000	1,000,000
Convertible Preferred stock, shares issued	264,894	264,894
Convertible Preferred stock, shares outstanding	264,894	264,894
Convertible Preferred Stock Series B [Member]
Convertible Preferred stock, par value (in dollars per share)	$ 0.001
Convertible Preferred stock, shares authorized	4,000,000
Convertible Preferred stock, shares issued	777,560	0
Convertible Preferred stock, shares outstanding	777,560	0

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue		$ 807		$ 2,253
Operating Expenses
Professional fees	241,454	131,988	1,145,895	448,812
Professional fees - related party	104,050	55,725	245,050	186,275
Management fee - related party	120,000	120,000	360,000	360,000
Personnel related expenses	428,633	311,556	1,998,460	868,602
Other selling, general and administrative	72,494	96,416	214,321	268,205
Total Operating Expenses	966,631	715,685	3,963,726	2,131,894
Loss before income taxes	(966,631)	(714,878)	(3,963,726)	(2,129,641)
Income taxes
Net Loss	$ (966,631)	$ (714,878)	$ (3,963,726)	$ (2,129,641)
Net loss per common share - basic and diluted	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.03)
Weighted average number of common shares outstanding during the periods - basic and diluted	93,506,088	74,640,786	88,660,995	72,874,854

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Series A Voting Preferred Stock$0.001 Par Value [Member[	Series B Voting Preferred Stock $0.001 Par Value [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 265		$ 69,642	$ 10,701,887	$ (10,228,833)	$ 542,961
Balance, Shares at Dec. 31, 2018	264,894		69,642,554
Proceeds received pursuant to Private Placement Memorandum, net of offering costs			$ 2,351	605,523		607,874
Proceeds received pursuant to Private Placement Memorandum, Shares			2,351,000
Common stock issued for services			$ 240	124,760		125,000
Common stock issued for services, Shares			240,000
Net Loss					(744,398)	(744,398)
Balance at Mar. 31, 2019	$ 265		$ 72,233	11,432,170	(10,973,231)	531,437
Balance, Shares at Mar. 31, 2019	264,894		72,233,554
Balance at Dec. 31, 2018	$ 265		$ 69,642	10,701,887	(10,228,833)	542,961
Balance, Shares at Dec. 31, 2018	264,894		69,642,554
Net Loss						(2,129,641)
Balance at Sep. 30, 2019	$ 265		$ 75,469	12,479,895	(12,358,474)	197,155
Balance, Shares at Sep. 30, 2019	264,894		75,468,722
Balance at Mar. 31, 2019	$ 265		$ 72,233	11,432,170	(10,973,231)	531,437
Balance, Shares at Mar. 31, 2019	264,894		72,233,554
Proceeds received pursuant to Private Placement Memorandum, net of offering costs			$ 1,472	390,155		391,627
Proceeds received pursuant to Private Placement Memorandum, Shares			1,471,500
Net Loss					(670,365)	(670,365)
Balance at Jun. 30, 2019	$ 265		$ 73,705	11,822,325	(11,643,596)	252,699
Balance, Shares at Jun. 30, 2019	264,894		73,705,054
Proceeds received pursuant to Private Placement Memorandum, net of offering costs			$ 1,711	631,289		633,000
Proceeds received pursuant to Private Placement Memorandum, Shares			1,711,000
Common stock issued for services			$ 53	26,281		26,334
Common stock issued for services, Shares			52,668
Net Loss					(714,878)	(714,878)
Balance at Sep. 30, 2019	$ 265		$ 75,469	12,479,895	(12,358,474)	197,155
Balance, Shares at Sep. 30, 2019	264,894		75,468,722
Balance at Dec. 31, 2019	$ 265		$ 80,953	13,966,326	(13,649,784)	397,760
Balance, Shares at Dec. 31, 2019	264,894		80,952,555
Proceeds received pursuant to Private Placement Memorandum, net of offering costs			$ 1,907	499,843		501,750
Proceeds received pursuant to Private Placement Memorandum, Shares			1,907,000
Common stock issued for services			$ 3,964	1,039,101		1,043,065
Common stock issued for services, Shares			3,964,375
Net Loss					(1,851,085)	(1,851,085)
Balance at Mar. 31, 2020	$ 265		$ 86,824	15,505,270	(15,500,869)	91,490
Balance, Shares at Mar. 31, 2020	264,894		86,823,930
Balance at Dec. 31, 2019	$ 265		$ 80,953	13,966,326	(13,649,784)	397,760
Balance, Shares at Dec. 31, 2019	264,894		80,952,555
Net Loss						(3,963,726)
Balance at Sep. 30, 2020	$ 265	$ 778	$ 95,808	18,250,569	(17,613,510)	733,910
Balance, Shares at Sep. 30, 2020	264,894	777,560	95,807,930
Balance at Mar. 31, 2020	$ 265		$ 86,824	15,505,270	(15,500,869)	91,490
Balance, Shares at Mar. 31, 2020	264,894		86,823,930
Proceeds received pursuant to Private Placement Memorandum, net of offering costs			$ 2,350	594,650		597,000
Proceeds received pursuant to Private Placement Memorandum, Shares			2,350,000
Proceeds received from sale of Preferred Stock		$ 500		499,500		500,000
Proceeds received from sale of Preferred Stock, Shares		500,000
Common stock issued for services			$ 1,880	468,120		470,000
Common stock issued for services, Shares			1,880,000
Net Loss					(1,146,010)	(1,146,010)
Balance at Jun. 30, 2020	$ 265	$ 500	$ 91,054	17,067,540	(16,646,879)	512,480
Balance, Shares at Jun. 30, 2020	264,894	500,000	91,053,930
Proceeds received pursuant to Private Placement Memorandum, net of offering costs			$ 3,754	906,746		910,500
Proceeds received pursuant to Private Placement Memorandum, Shares			3,754,000
Proceeds received from sale of Preferred Stock		$ 278		277,283		277,561
Proceeds received from sale of Preferred Stock, Shares		277,560
Common stock issued to related party (unaudited)			$ 1,000	(1,000)
Common stock issued to related party (unaudited) Shares			1,000,000
Net Loss					(966,631)	(966,631)
Balance at Sep. 30, 2020	$ 265	$ 778	$ 95,808	$ 18,250,569	$ (17,613,510)	$ 733,910
Balance, Shares at Sep. 30, 2020	264,894	777,560	95,807,930

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Offering costs	$ 0	$ 3,000	$ 0	$ 0	$ 0	$ 0

XML 20 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (3,963,726)	$ (2,129,641)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	3,000	3,000
Stock issued as compensation for services	1,513,065	121,334
Changes in operating assets and liabilities:
Accounts receivable - related party	(297,630)	160,590
Accounts payable and accrued expenses	187,709	51,166
Accounts payable and accrued expenses - related party	(241,870)	20,319
Right-of-use operating lease asset	51,970	49,047
Operating lease liability	(52,182)	(44,991)
Net cash used in operating activities	(2,799,664)	(1,769,176)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment	(8,874)	(8,880)
Website development costs	(70,760)	(5,247)
Net cash used in investing activities	(79,634)	(14,127)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of common stock, net of offering costs	2,009,250	1,632,501
Proceeds from the sale of preferred stock	777,561
Proceeds from long term debt	165,719
Net cash provided by financing activities	2,952,530	1,632,501
Net increase (decrease) in cash	73,232	(150,802)
Cash at beginning of period	446,219	201,509
Cash at end of period	519,451	50,707
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid in cash
Income taxes paid in cash
Non-cash transactions:
Reclassification of stock compensation from other liabilities to common stock		30,000
Right-of-use asset obtained in exchange for operating lease liabilities		179,341
Common stock issued to related party	$ 1,000

XML 21 R8.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operation

9 Months Ended

Sep. 30, 2020

Organization Going Concern And Summary Of Significant Accounting Policies

Organization and Nature of Operation

Note 1 - Organization and Nature of Operation

XML 22 R9.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Sep. 30, 2020

Numerator:

Going Concern

Note 2 – Going Concern

XML 23 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

These condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates

Subsequent Events

Risks and Uncertainties

Income Taxes

Revenue Recognition

Revenue is recognized at point of sale, with no further obligations.

Share Based Payment Arrangements

Loss Per Share

Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019:


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2020			2019			2020			2019
Basic and Diluted LPS Computation
Numerator:
Loss available to common stockholders	$	(966,631	)	$	(714,878	)	$	(3,963,726	)	$	(2,129,641	)

Denominator:
Weighted average number of common shares outstanding		93,506,088			74,640,786			88,660,995			72,874,854

Basic and diluted LPS	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.03	)


Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	3,110,240	—	3,110,240	—

Recent Accounting Pronouncements

Recoverability of Long-Lived Assets

Website and Development Costs

XML 24 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions

Note 4 – Related Party Transactions

Prepaid expenses / (Accounts payable and accrued expenses) to related parties are as follows:


Related Party	At September 30, 2020			At December 31, 2019
TBG	$	297,630		$	(241,870	)
R3		(19,931	)		(19,931	)
	$	277,699		$	(261,801	)

EGG Agreement

XML 25 R12.htm IDEA: XBRL DOCUMENT

Long Term Debt

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Long Term Debt

Note 5 – Long Term Debt

XML 26 R13.htm IDEA: XBRL DOCUMENT

Preferred Stock

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Preferred Stock

Note 6 – Preferred Stock

(a) Automatic Conversion

(b) Optional Conversion

Dividends

Voting Rights

XML 27 R14.htm IDEA: XBRL DOCUMENT

Pending Legal Matters

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Pending Legal Matters

Note 7 – Pending Legal Matters

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC.

XML 28 R15.htm IDEA: XBRL DOCUMENT

COVID 19 Pandemic

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

COVID 19 Pandemic

Note 8 – COVID 19 Pandemic

XML 29 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

These condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates

Use of Estimates

Subsequent Events

Subsequent Events

Management has evaluated events occurring subsequent to the condensed consolidated balance sheet date, through November 16, 2020, which is the date the condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

Risks and Uncertainties

Risks and Uncertainties

Income Taxes

Income Taxes

Revenue Recognition

Revenue Recognition

Revenue is recognized at point of sale, with no further obligations.

Share Based Payment Arrangements

Share Based Payment Arrangements

Loss Per Share

Loss Per Share

Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019:


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2020			2019			2020			2019
Basic and Diluted LPS Computation
Numerator:
Loss available to common stockholders	$	(966,631	)	$	(714,878	)	$	(3,963,726	)	$	(2,129,641	)

Denominator:
Weighted average number of common shares outstanding		93,506,088			74,640,786			88,660,995			72,874,854

Basic and diluted LPS	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.03	)


Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	3,110,240	—	3,110,240	—

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recoverability of Long-Lived Assets

Recoverability of Long-Lived Assets

Website and Development Costs

Website and Development Costs

XML 30 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of computation of basic and diluted net loss per share

Following is the computation of basic and diluted loss per share for the three and nine month periods ended September 30, 2020 and 2019:


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2020			2019			2020			2019
Basic and Diluted LPS Computation
Numerator:
Loss available to common stockholders	$	(966,631	)	$	(714,878	)	$	(3,963,726	)	$	(2,129,641	)

Denominator:
Weighted average number of common shares outstanding		93,506,088			74,640,786			88,660,995			72,874,854

Basic and diluted LPS	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.03	)

Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share


Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	3,110,240	—	3,110,240	—

XML 31 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of accounts receivable (accounts payable and accrued expenses) to related parties

Accounts receivable / (Accounts payable and accrued expenses) to related parties are as follows:


Related Party	At September 30, 2020			At December 31, 2019
TBG	$	297,630		$	(241,870	)
R3		(19,931	)		(19,931	)
	$	277,699		$	(261,801	)

XML 32 R19.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	2 Months Ended	9 Months Ended
Going Concern (Details Narrative) - USD ($)	Nov. 16, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accumulated deficit		$ 17,613,510		$ 13,649,784
Proceeds from stock issued		$ 2,009,250	$ 1,632,501
Subsequent Event [Member] \| Restricted Common Stock [Member]
Stock issued	703,000
Proceeds from stock issued	$ 192,000
Subsequent Event [Member] \| Convertible Preferred Stock Series B [Member]
Stock issued	660,000
Proceeds from stock issued	$ 660,000

XML 33 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Schedule of Basic and Diluted LPS) (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Loss available to common stockholders	$ (966,631)	$ (1,146,010)	$ (1,851,085)	$ (714,878)	$ (670,365)	$ (744,398)	$ (3,963,726)	$ (2,129,641)
Denominator:
Weighted average number of common shares outstanding	93,506,088			74,640,786			88,660,995	72,874,854
Basic and diluted LPS	$ (0.01)			$ (0.01)			$ (0.04)	$ (0.03)
Convertible Preferred Stock Series A [Member]
Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
Preferred stock (convertible)	24,900,000			24,900,000			24,900,000	24,900,000
Convertible Preferred Stock Series B [Member]
Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
Preferred stock (convertible)	3,110,240						3,110,240

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 34 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Website and development costs	$ 427,464	$ 356,704

XML 35 R22.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounts payable and accrued expenses - related party	$ (19,931)	$ (261,801)
Prepaid expenses - related party	297,630
TBG Holdings Corp. [Member]
Accounts payable and accrued expenses - related party		(241,870)
Prepaid expenses - related party	297,630
R3Accounting, LLC [Member]
Accounts payable and accrued expenses - related party	$ (19,931)	$ (19,931)

XML 36 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jul. 27, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Fee for accounting services		$ 104,050	$ 55,725	$ 245,050	$ 186,275
Management fee - related party		120,000	120,000	360,000	360,000
Stock issued from EGG to Turnkey						1,000,000
Prepaid management fees - related party		297,630		297,630
Common Stock [Member]
Related Party Transaction [Line Items]
Common stock issued to related party (unaudited)		1,000
TBG Holdings Corp. [Member]
Related Party Transaction [Line Items]
Management fee - related party		120,000	120,000	360,000	360,000
Management agreement description	Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG Holdings Corp. (“TBG”) was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Neil Swartz and Timothy Hart are members of the Company’s Board of Directors. Under this agreement, we pay TBG a monthly fee of $40,000.
Monthly management fee	$ 40,000
Prepaid management fees - related party		297,630		297,630
R3Accounting, LLC [Member]
Related Party Transaction [Line Items]
Fee for accounting services		$ 104,050	$ 55,725	$ 245,050	$ 186,275

XML 37 R24.htm IDEA: XBRL DOCUMENT

Long Term Debt (Details)	9 Months Ended
Long Term Debt (Details)	Sep. 30, 2020 USD ($)
Debt Disclosure [Abstract]
PPP loan	$ 165,719
Interest rate	1.00%
Maturity date	May 31, 2022

XML 38 R25.htm IDEA: XBRL DOCUMENT

Preferred Stock (Details Narrative) - USD ($)	9 Months Ended
Preferred Stock (Details Narrative) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Convertible Preferred Stock Series A [Member]
Convertible Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible Preferred Series A stock, shares authorized	1,000,000	1,000,000
Convertible Preferred stock, shares outstanding	264,894	264,894
Number of common stock issuable for total shares of convertible preferred stock	24,900,000
Convertible Preferred Stock Series B [Member]
Convertible Preferred stock, par value (in dollars per share)	$ 0.001
Convertible Preferred Series A stock, shares authorized	4,000,000
Convertible Preferred stock, shares outstanding	777,560	0
Dividend rate	8.00%
Dividends	$ 13,106

XML 39 R26.htm IDEA: XBRL DOCUMENT

Pending Legal Matters (Details Narrative)	Sep. 30, 2013 USD ($)
TBG Holdings Corp. [Member]
Monthly management fee	$ 40,000

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end